Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770387 | 0.87 | MARS1 (0.41) | AGTR1AGTR2BCL2MDM2MCL1 | |
| SCHEMBL3702552 | 0.85 | AGTR1 (0.40) | PTGER1AGTR1AGTR2P2RY14BDKRB1 | |
| SCHEMBL655667 | 0.85 | MME (0.43) | MMECYP3A4CTSA | |
| SCHEMBL652659 | 0.85 | MME (0.43) | AGTR1MMEAGTR2ECE1BDKRB1 | |
| SCHEMBL655668 | 0.85 | MME (0.43) | MMECYP3A4CTSA | |
| SCHEMBL652502 | 0.84 | MME (0.43) | PTGER1AGTR1MMEAGTR2ECE1 | |
| SCHEMBL652695 | 0.84 | MME (0.43) | AGTR1MMEAGTR2ECE1BDKRB1 | |
| SCHEMBL1927723 | 0.77 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL16796466 | 0.77 | P2RY14 (0.54) | PTGER1P2RY14BCL2MDM2MCL1 | |
| SCHEMBL976879 | 0.76 | AGTR1 (0.36) | AGTR1MMEAGTR2ECE1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451782-B1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8822522-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | disclosed |
| US-8350027-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2451782-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | PTGER1 175/4885AGTR1 1/4885MME 10/4885 |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | PTGER1 175/4885AGTR1 1/4885MME 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.